Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery

Recombinant factor VIIa (rFVIIa: NovoSeven; Novo Nordisk) has proven efficacy in the treatment of haemophilic patients with inhibitors. This prospective, double-blind study compared rFVIIa (35 vs. 90 microg/kg) in the initiation and maintenance of haemostasis during and after elective surgery. Patients with inhibitors (FVIII, n = 26; FIX, n = 3) received rFVIIa immediately prior to incision; intraoperatively as needed; every 2 h for the first 48 h; and every 2-6 h for the following 3 days. Haemostasis was evaluated during surgery, at 0, 8, 24 and 48 h and 3, 4 and 5 days after wound closure. After day 5, open-label rFVIIa (90 microg/kg) was available for maintenance. Intraoperative haemostasis was achieved in 28/29 patients. All high-dose patients and 12/15 low dose patients had satisfactory haemostasis during the first 48 h. Twenty-three patients (13/14 high dose) successfully completed the study. Although the 35 microg/kg dose is probably sub-optimal for post-operative management, at least in major procedures, rFVIIa 90 microg/kg is an effective first-line option in surgery for patients with inhibitors.

[1]  R. Bech.  Recombinant factor VIIa in joint and muscle bleeding episodes. , 1996, Haemostasis.

[2]  J. Lusher.  Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. , 1996, Haemostasis.

[3]  E. Santagostino,et al.  Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. , 1994, Seminars in hematology.

[4]  U. Hedner,et al.  Clinical update on the use of recombinant factor VII. , 1995, Advances in experimental medicine and biology.

[5]  M. Blombäck,et al.  SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY , 1988, The Lancet.

[6]  S. Glazer,et al.  Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. , 1993, The American journal of pediatric hematology/oncology.

[7]  A. O'marcaigh,et al.  Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor. , 1994, Mayo Clinic proceedings.

[8]  B. Macik.  Treatment of factor VIII inhibitors: products and strategies. , 1993, Seminars in thrombosis and hemostasis.

[9]  G. Savidge,et al.  NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds. , 1996, Haemostasis.

[10]  M. Read,et al.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Woods,et al.  Effect of surgical operations on certain tests used to diagnose intravascular coagulation and fibrinolysis. , 1974, Mayo Clinic proceedings.

[12]  R. Thorpe,et al.  Monoclonal antibodies to crosslinked fibrin degradation products (XL‐FDP) II. EVALUATION IN A VARIETY OF CLINICAL CONDITIONS , 1988, British journal of haematology.

[13]  Macik Bg.  Treatment of Factor VIII Inhibitors: Products and Strategies , 1993, Seminars in thrombosis and hemostasis.

[14]  W. T. Sawyer,et al.  Pharmacokinetics and pharmacodynamics of recombinant factor VIIa , 1994, Clinical pharmacology and therapeutics.

[15]  J. Scott,et al.  Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia a patients with inhibitors , 1994, American journal of hematology.

[16]  J. Lusher,et al.  Clinical experience with recombinant factor VIIa. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  U. Hedner,et al.  Immunological Aspects of Recombinant Factor Vila (rFVIIa) in Clinical Use , 1996, Thrombosis and Haemostasis.

[18]  D. Brettler,et al.  The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. , 1989, Archives of internal medicine.

[19]  E. Gordon,et al.  A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.

[20]  J. Lusher,et al.  Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations. , 1994, Seminars in hematology.

[21]  U. Hedner,et al.  Management of hemophilia patients with inhibitors. , 1992, Hematology/oncology clinics of North America.

[22]  S. Rapaport,et al.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Scheibel,et al.  Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. , 1996, Haemostasis.

[24]  S. Schulman,et al.  Feasibility of Using Recombinant Factor VIIa in Continuous Infusion , 1996, Thrombosis and Haemostasis.

[25]  E. Berntorp,et al.  Treatment of Patients with Factor VIII and IX Inhibitors , 1993, Thrombosis and Haemostasis.